INTRODUCTION
Two pivotal phase III trials have laid the foundation for using targeted antiangiogenic agents in the treatment of metastatic nonsquamous non-small-cell lung cancer (NSCLC). In the E4599 study, treatment with bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, combined with carboplatin/paclitaxel significantly improved objective response rate (ORR), progressionfree survival (PFS), and overall survival (OS) compared with carboplatin/paclitaxel alone. 1 In the AVAiL (AVAstin in Lung) study, bevacizumab plus cisplatin/gemcitabine improved PFS and ORR, compared with placebo, but not OS. 2, 3 Efforts to identify drugs that inhibit key signaling pathways involved in the pathogenesis of cancer have led to the development of multitargeted agents. Small-molecule tyrosine kinase inhibitors that block several kinases simultaneously may offer advantages over single-target agents. 4 Furthermore, there is interest in identifying patients most likely to respond to targeted therapies based on specific biomarkers 5 and/or tumor histology. 6 
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Motesanib is a selective oral inhibitor of VEGF receptors (VEGFR) 1, 2, and 3; platelet-derived growth factor receptor; and Kit 7 that has demonstrated antitumor activity when administered as monotherapy [8] [9] [10] or combined with chemotherapy. 11 In a phase II randomized, open-label study in advanced nonsquamous NSCLC, ORR, PFS, and OS were estimated to be comparable among patients who received carboplatin/paclitaxel and either motesanib 125 mg once daily (n ϭ 61) or bevacizumab 15 mg/kg once every 3 weeks (n ϭ 63).
11 A biomarker analysis of that study showed significant associations between increase in placental growth factor (PLGF) during the first 3 weeks of treatment and efficacy outcomes in the motesanib 125-mg once daily arm. 12 PLGF is a VEGF homolog that can promote angiogenesis by activating VEGFR-1. 13 The primary objective of the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study was to determine whether motesanib combined with carboplatin/paclitaxel improved OS, compared with placebo plus carboplatin/paclitaxel, in patients with advanced nonsquamous NSCLC and in the subset of patients with adenocarcinoma histology. We also assessed whether increases in PLGF during motesanib treatment were associated with OS.
PATIENTS AND METHODS

Eligibility
Initially, the study enrolled patients with NSCLC of all histologies. After a planned review of data from 600 patients (including 223 with squamous histology) in November 2008, the independent data monitoring committee recommended that enrollment of all patients be halted and treatment of those with squamous histology be discontinued because of higher early mortality and a higher incidence of gross hemoptysis compared with placebo. Patients with nonsquamous histology continued to receive treatment. The study protocol was amended in April 2009 to only allow enrollment of patients with nonsquamous histology; enrollment resumed in June 2009. This article reports results from the amended study.
Eligible patients (Ն 18 years of age) had histologically confirmed unresectable stage IIIB with pericardial/pleural effusion or stage IV/recurrent nonsquamous NSCLC; measurable or nonmeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST 1.0) 14 ; Eastern Cooperative Oncology Group performance status Յ 1; life expectancy Ն 3 months; and adequate renal, cardiac, hepatic, and hematologic function. Key exclusion criteria were history of pulmonary hemorrhage or gross hemoptysis within 6 months of randomization; prior chemotherapy, including adjuvant chemotherapy within 52 weeks of randomization; symptomatic or untreated CNS metastases; adenosquamous histology or unclear histologic type (Ͼ 10% squamous cells); prior targeted therapy; uncontrolled hypertension; arterial or venous thrombosis within 12 months, or bleeding diathesis or bleeding within 14 days of randomization. Study procedures were approved by an independent ethics committee/institutional review board at each study site. All patients provided written informed consent.
Study Design and Treatments
The study was conducted at 198 centers in 32 countries. Patients received paclitaxel (200 mg/m 2 ) and carboplatin (area under the curve, 6 mg/ml · min) on day 1 of each 3-week cycle for up to six cycles and were randomly assigned 1:1 using a computerized interactive voice response system to also receive oral motesanib 125 mg once daily (arm A) or placebo (arm B). Randomization was stratified by disease stage (IIIB v IV/recurrent), weight loss in the previous 6 months before randomization (Ͻ 5% v Ն 5%), sex (male v female), and prior adjuvant chemotherapy (yes v no). Treatment continued until disease progression, unacceptable toxicity, or withdrawal of consent.
In case of treatment-related grade 3 or 4 toxicity, motesanib/placebo was withheld until the toxicity resolved to grade Յ 1 or baseline. Treatment could then be resumed with a 25-mg dose reduction but was permanently discontinued if more than two dose reductions were required or if grade 3 or 4 toxicity recurred after a dose delay and/or reduction or persisted for more than 3 weeks.
The primary end point was OS. Secondary end points included PFS (from randomization to disease progression per RECIST), ORR per RECIST 1.0, and incidence of adverse events (AEs). Before unblinding, the statistical analysis plan was amended to also assess association between motesanib treatment-induced PLGF change and OS as a secondary end point.
Assessments
Computed tomography/magnetic resonance imaging was performed every 6 Ϯ 1 weeks for assessment of tumor response by investigators. Objective responses were confirmed Ն 4 weeks after the initial response assessment. If symptoms suggestive of disease progression occurred, patients were evaluated for tumor response.
All AEs (from the start of treatment to 30 days after the last dose) were recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.
Biomarker Analysis
Serum samples were obtained before treatment on day 1 of cycles 1, 2, and 3 and every 6 weeks thereafter. Serum PLGF was quantified using a two-step chemiluminescent microparticle immunoassay (ARCHITECT; Abbott Laboratories, Abbott Park, IL). Briefly, serum sample and anti-PLGF antibody paramagnetic microparticles were incubated together; following a wash step, anti-PLGF acridinium-labeled antibody was added. After another incubation and wash, pretrigger and trigger solutions were added, and chemiluminescent signal was measured. The lower limit of quantitation was 3.4 pg/mL; the linear response range was 4 to 1,500 pg/mL.
Statistical Analysis
The study was designed to accrue approximately 1,060 patients with nonsquamous histology to have 80% power to detect a hazard ratio (HR) of 0.80 (12.5 months v 10 months) for OS with two-sided ␣ ϭ .03 in the patients with nonsquamous histology. The study had 80% power to detect an HR of 0.77 (13 months v 10 months) for OS with two-sided ␣ ϭ .02 in the adenocarcinoma subset. An ␣ split testing strategy was used to control the overall type I error rate of the study. The primary analysis was planned at 742 and 593 deaths among patients with nonsquamous histology and the adenocarcinoma subset, respectively, whichever occurred later. An interim analysis was planned at 370 events among nonsquamous patients; early stopping guidelines are described in the study protocol (Data Supplement).
OS and PFS were compared between arms A and B using stratified log-rank tests based on the stratification factors at randomization. HRs for the effect of motesanib on OS and PFS between arms A and B were estimated using a stratified Cox proportional hazards model. 15 Difference in ORR between arms A and B was calculated with a stratified Cochran-Mantel-Haenszel test 15 using the randomization stratification factors. The association between motesanib treatment-induced PLGF change and OS was evaluated using a Cox model with the log-transformed fold-change in PLGF from baseline at week 4 as a continuous variable. If OS and PLGF were significantly associated, foldchange in PLGF was to be assessed based on a prespecified cutoff (Ն 2.0-fold v Ͻ 2.0-fold change). A hierarchical testing scheme for the secondary efficacy end points (PFS, PLGF, and ORR) was specified if the primary end point (OS) was met.
Efficacy analyses for OS and PFS included all randomly assigned patients with nonsquamous histology following the intent-to-treat principle. Safety analyses included all randomly assigned patients who received one or more doses of motesanib/placebo. Biomarker analyses included all patients randomly assigned who had PLGF values at weeks 1 (baseline) and 4 and had received motesanib/placebo the day before the week 4 PLGF sample collection.
RESULTS
Patients
Between July 5, 2007, and March 18, 2010, 1,090 patients with nonsquamous NSCLC were randomly assigned to motesanib (n ϭ 541; arm A) or placebo (n ϭ 549; arm B). Before the protocol amendment, the study also enrolled 360 patients with squamous histology. Data from this cohort will be reported in a separate publication. Eighteen patients with nonsquamous NSCLC did not receive motesanib (n ϭ 10) or placebo (n ϭ 8; Fig 1) . Most patients had adenocarcinoma histology (arm A, 83%; arm B, 81%), weight loss less than 5% in the previous 6 months, and stage IV/recurrent disease ( Table 1) . Clinical characteristics were generally balanced across treatment arms.
Treatment
Median daily doses of motesanib or placebo were 125 mg in both treatment arms. Patients received motesanib for a median of 4.1 months (range, 0.03 to 35.9 months) and placebo for 4.1 months (range, 0.03 to 31.5 months). Carboplatin was administered for a median of 4.5 cycles (range, one to six cycles) in arm A and 5.0 cycles (range, one to six cycles) in arm B; paclitaxel was administered for a median of 4.0 cycles (range, one to six cycles) in arm A and 5.0 cycles (range, one to six cycles) in arm B. At the time of this analysis, 519 patients (96%) in arm A and 534 patients (97%) in arm B had discontinued motesanib/placebo; more patients in arm A than arm B had discontinued for reasons other than disease progression (Fig 1) . Median follow-up times were 11 months (range, 0.2 to 41 months) in arm A and 10 months (range, 0.2 to 38 months) in arm B.
OS
Treatment with motesanib did not significantly improve OS. At the time of this analysis, 66% of patients in arm A and 72% in arm B had died. Among all patients with nonsquamous histology, median OS times were 13.0 months (95% CI, 11.2 to 14.0 months) in arm A versus 11.0 months (95% CI, 10.1 to 12.4 months) in arm B (HR, 0.90; 95% CI, 0.78 to 1.04; P ϭ .14; Fig 2A) . In the adenocarcinoma subset, median OS time was 13.5 months (95% CI, 11.3 to 14.7 months) in arm A versus 11.0 months (95% CI, 9.9 to 12.4 months) in arm B (HR, 0.88; 95% CI, 0.75 to 1.03; P ϭ .11; Fig 2B) . Prespecified subgroup analyses suggested longer survival among patients receiving motesanib who were nonwhite (HR, 0.76; 95% CI, 0.59 to 0.97; n ϭ 375) or who were enrolled outside the United States/Canada/Australia/European Union (HR, 0.77; 95% CI, 0.61 to 0.98; n ϭ 414; Fig 3) .
PFS
Among all patients with nonsquamous histology, median PFS times were 5.6 months in arm A versus 5.4 months in arm B (HR, 0.79; 95% CI, 0.68 to 0.90; P ϭ Ͻ .001; Fig 4A) .
PFS times in the adenocarcinoma
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All randomly assigned patients with nonsquamous histology (n = Fig 4B) . P values for PFS and other secondary efficacy end points are exploratory because the study end point (OS) was not achieved.
Tumor Response
Most patients had measurable disease at baseline (Table 2) . In exploratory analyses, ORR for all patients with nonsquamous histology (arm A, 40% v arm B, 26%) and for the adenocarcinoma subset (arm A, 39% v arm B, 25%) favored arm A. Likewise, in both the overall nonsquamous population (arm A, 80% v arm B, 74%) and the adenocarcinoma subset (arm A, 81% v arm B, 74%), more patients receiving motesanib than placebo had a decrease in the sum of longest diameter at any time after baseline. Duration of response was 5.8 months (95% CI, 5.3 to 6.5 months) in arm A and 5.0 months (95% CI, 4.4 to 5.6 months) in arm B.
Toxicity
Toxicity data are reported for all randomly assigned patients with nonsquamous histology. The incidence of grade 3 AEs was similar with both treatments; however, grade 4 and grade 5 AEs as well as serious grade Ն 3 AEs occurred more frequently in arm A (Table 3) . No specific events accounted for the imbalance in the incidence of grade 4 or 5 AEs with the exception of grade 4 neutropenia (12% of patients in arm A v 6% in arm B). Considering all AEs, there were a number of events that occurred at an increased incidence of Ն 5% in arm A compared with placebo (Table 3) . Particularly noteworthy were diarrhea, nausea, vomiting, and abdominal pain as well as hypertension, pneumonia, and gallbladder-related disorders (eg, cholecystitis, cholelithiasis, and gallbladder enlargement), some of which were also reported as serious grade Ն 3 AEs.
The incidence of AEs typically associated with VEGF pathway inhibitors was higher in arm A with respect to hypertension (Table 3) and grade Ն 3 arterial thromboembolic (2% v Ͻ 1% in arm B) and hemorrhagic events (3% v 1%). Specific hemorrhagic events were gastrointestinal hemorrhage (n ϭ 1 v n ϭ 0), pulmonary hemorrhage (n ϭ 2 v n ϭ 1), and hemoptysis (n ϭ 3 v n ϭ 1). Grade Ն 3 venous thromboembolic events occurred in 4% of patients in each treatment arm.
The number of patients with AEs leading to motesanib/placebo discontinuation was higher in arm A (31%) than in arm B (15%). Fourteen percent of patients in arm A and 9% in arm B had fatal AEs while on study (ie, within 30 days of the last study treatment). 
Fig 2.
Overall survival (OS) time among patients who received motesanib 125 mg once daily plus carboplatin/paclitaxel (C/P) or placebo plus C/P in (A) all randomly assigned patients with nonsquamous histology and (B) the adenocarcinoma subset. Abbreviations: C/P, carboplatin/paclitaxel; ECOG, Eastern Cooperative Oncology Group.
‫ء‬
All randomly assigned patients with nonsquamous histology. ‡Randomization stratification factors. §Includes Japanese patients.
pneumonia (n ϭ 7 v n ϭ 0), general physical health deterioration (n ϭ 6 v n ϭ 1), respiratory failure (n ϭ 5 v n ϭ 2), pulmonary embolism (n ϭ 3 v n ϭ 6), and cardiorespiratory arrest (n ϭ 1 v n ϭ 4).
Assessment of PLGF As a Biomarker
MONET1 confirmed the pharmacodynamic increase in PLGF in response to motesanib treatment that was reported previously 9, 12, 16, 17 (data not shown). However, among patients in the motesanib arm who had evaluable PLGF samples at baseline (n ϭ 356, 33%), there was no association between the log-transformed fold-change in PLGF from baseline to week 4 (continuous variable) and OS (unadjusted Cox model, HR, 0.98; 95% CI, 0.79 to 1.22; P ϭ .868). There was no association between the prespecified Ն 2.0-fold change in PLGF from baseline at week 4 and OS (HR, 0.88; 95% CI, 0.67 to 1.15, P ϭ .340). Similarly, there was no association between a Ն 2.0-fold change in PLGF and PFS or ORR.
DISCUSSION
In this large phase III study, motesanib plus carboplatin/paclitaxel did not significantly improve OS compared with placebo plus carboplatin/paclitaxel in the overall nonsquamous patient population or the subset of patients with adenocarcinoma. Although the study did not meet its primary end point, improvements in PFS and ORR in arm A suggest some antitumor activity of the combination in this setting. However, the study also showed that motesanib treatment was associated with increased toxicity, which may have affected efficacy. Specifically, the incidence of grade 4 and 5 AEs, serious grade Ն 3 AEs, and AEs leading to discontinuation was higher with motesanib treatment. Gastrointestinal events, hypertension, pneumonia, cholecystitis, and other gallbladder-related disorders generally occurred more frequently in the motesanib arm, which is consistent with previous motesanib studies in advanced nonsquamous NSCLC.
11, 18 Cholecystitis in particular is a motesanib-specific AE that had emerged in earlier monotherapy and chemotherapy combination studies. 8,9,11,18-20 Most of these AEs are likely the result of motesanib's actions on angiogenic signaling pathways (motesanib potently inhibits VEGFR1, -2, and -3; Kit; and PDGFR 7 ). Toxicity in the motesanib arm appeared to have contributed to treatment discontinuation and may also have resulted in noncompliance with treatment. The study initially permitted enrollment of both nonsquamous and squamous NSCLC; however, the protocol was later amended to 32  64  96  128  160  8  40  72  104  144  16  48  80  112  24  56  88  120  136  152 Fig 4. Progression-free survival time among patients who received motesanib 125 mg once daily plus carboplatin/paclitaxel (C/P) or placebo plus C/P in (A) all randomly assigned patients with nonsquamous histology and (B) the adenocarcinoma subset. 5.3 to 6.5 4.4 to 5.6 5.5 to 6.9 4.4 to 5.7
Abbreviations: C/P, carboplatin/paclitaxel; CR, complete response; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.
‫ء‬
Assessed by investigators per RECIST version 1.0. The nonsquamous analysis set included all patients randomly assigned who had nonsquamous histology. The adenocarcinoma analysis set included all patients randomly assigned who had adenocarcinoma histology. The denominator for all response categories was the number of patients with measurable disease at baseline.
†Patients with an assessment of PR or CR not confirmed at least 4 weeks later were classified as having SD. ‡Patients with an assessment of CR, PR, or SD before the first scheduled assessment of response without an additional assessment of response. §Patients for whom imaging was not performed at the scheduled assessment of response.
From Cochran-Mantel-Haenszel test stratified by the randomization stratification factors.
febrile neutropenia and was not considered tolerable. 24 Furthermore, two randomized studies evaluating VEGF pathway inhibitors as second-line therapy in advanced NSCLC failed to meet their primary end points. 25, 26 The results from MONET1 add to the growing body of evidence suggesting that VEGF pathway inhibitors in combination with chemotherapy do not provide a significant clinical benefit to unselected patients with (nonsquamous) NSCLC. Additional studies do not seem to be warranted unless better patient selection using biomarkers, for example, can be achieved. Despite ongoing efforts, 27 such biomarkers have remained elusive. MONET1 is the first large phase III study to prospectively test a biomarker hypothesis for an antiangiogenic therapy in NSCLC. Data from the preceding phase II study of carboplatin/paclitaxel plus motesanib or bevacizumab suggested that increased PLGF might be a marker of therapeutic response to motesanib treatment. 12 This hypothesis was supported by similar findings of associations between fold-change in PLGF and outcomes in patients with advanced thyroid cancer 17 and human epidermal growth factor receptor 2-negative metastatic breast cancer 12 receiving motesanib. However, the data could not be confirmed in MONET1; there was no association between changes in PLGF and OS in the motesanib arm.
Previous studies suggested that NSCLC tumor histology influences response to certain chemotherapy regimens 28 and targeted agents (including VEGF pathway inhibitors).
6,29 A retrospective analysis of the E4599 study reported a 4-month improvement in OS with the addition of bevacizumab to carboplatin/paclitaxel among patients with adenocarcinoma histology. 6 On the basis of those data, we conducted a prospectively defined analysis of efficacy in the subset of patients with adenocarcinoma histology. Although a statistically significant improvement in OS was not achieved, it is noteworthy that in prespecified subgroup analyses, the HR for patients with adenocarcinoma histology was 0.880 versus 1.012 for those with other nonsquamous histologies.
Prespecified subgroup analyses also indicated differences in OS by ethnicity and geographic location. The subanalyses data suggest that a highly selected patient population might have a greater likelihood to benefit. Specifically, results from the ethnicity/regional subanalysis indicate that Asian patients (one fourth of the enrolled patient population) may achieve better clinical outcome than nonAsian patients (data not shown), which may warrant a separate study in the future.
In summary, treatment with motesanib plus carboplatin/paclitaxel in this phase III study did not significantly improve OS and was associated with a higher incidence of AEs compared with placebo plus carboplatin/paclitaxel in patients with advanced nonsquamous NSCLC and in the subset of patients with adenocarcinoma histology.
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